Grant Sean
Known title: Chief Financial OfficerCIK: 0001872792
Grant Sean's purchase track record
How the stock did after each of Grant Sean's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since February 6, 2022
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-8.2%
3 months: -15.9%
Beat the S&P 500
33%
median -4.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/23/2023 | VERA | $83K | -15.9% | -8.2% | +9.3% |
| 6/15/2022 | VERA | $68K | +51.0% | +45.0% | +5.4% |
| 2/6/2022 | VERA | $100K | -18.4% | -11.7% | -7.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VERA | ▼ Sell | Open Market | 4,949 | $208K | 2/23/2026 | View on chart |
| VERA | ▲ Buy | Grant | 25,000 | $0 | 2/4/2026 | View on chart |
| VERA | ▲ Buy | Grant | 26,900 | $0 | 2/18/2025 | View on chart |
| VERA | ▼ Sell | Open Market | 69,831 | $2.8M | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 7,361 | $289K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 78 | $3K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 867 | $35K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 1,505 | $60K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 203 | $8K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 453 | $18K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 3,112 | $119K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 2,944 | $115K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 6,965 | $279K | 4/3/2024 | View on chart |
| VERA | ▲ Buy | Option Exercise | 99,828 | $1.5M | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 639 | $25K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 80 | $3K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 387 | $15K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 366 | $14K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 177 | $7K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 672 | $26K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 201 | $8K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 10,988 | $425K | 4/3/2024 | View on chart |
| VERA | ▼ Sell | Open Market | 11,648 | $444K | 4/3/2024 | View on chart |
| VERA | ▲ Buy | Grant | 26,250 | $0 | 1/16/2024 | View on chart |
| VERA | ▼ Sell | Gift | 636 | $0 | 12/20/2023 | View on chart |
| VERA | ▼ Sell | Gift | 1,620 | $0 | 7/24/2023 | View on chart |
| VERA | ▼ Sell | Gift | 1,620 | $0 | 7/24/2023 | View on chart |
| VERA | ▲ Buy | Open Market | 5,000 | $83K | 6/23/2023 | View on chart |
| VERA | ▼ Sell | Gift | 14,285 | $0 | 3/14/2023 | View on chart |
| VERA | ▼ Sell | Gift | 14,285 | $0 | 3/14/2023 | View on chart |
| VERA | ▲ Buy | Grant | 33,750 | $0 | 8/19/2022 | View on chart |
| VERA | ▲ Buy | Open Market | 992 | $13K | 6/15/2022 | View on chart |
| VERA | ▲ Buy | Open Market | 335 | $5K | 6/15/2022 | View on chart |
| VERA | ▲ Buy | Open Market | 2,816 | $38K | 6/15/2022 | View on chart |
| VERA | ▲ Buy | Open Market | 857 | $12K | 6/15/2022 | View on chart |
| VERA | ▲ Buy | Open Market | 14,285 | $100K | 2/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Leerink Partners Covers Vera Therapeutics at $34 Target
Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.
Leerink Partners Covers Vera Therapeutics at $34 Target. Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.